Peacock S - Search Results

1

Cost-effectiveness of rituximab in follicular lymphoma.

Johnston KM, Bolbocean C, Connors J, Peacock S. Johnston KM, et al. Among authors: peacock s. Expert Rev Pharmacoecon Outcomes Res. 2012 Oct;12(5):569-77. doi: 10.1586/erp.12.57. Epub 2012 Nov 11. Expert Rev Pharmacoecon Outcomes Res. 2012. PMID: 23140274 Review.

2

Why should dentists screen for oral cancer?

Musa Z, Johnston K, Peacock S, Rosin MP, Elwood JM. Musa Z, et al. Among authors: peacock s. J Can Dent Assoc. 2008 Apr;74(3):243-4. J Can Dent Assoc. 2008. PMID: 18387265 Free article. No abstract available.

3

Verification of imatinib cost-effectiveness in advanced gastrointestinal stromal tumor in British Columbia (VINCE-BC study).

Mabasa VH, Taylor SC, Chu CC, Moravan V, Johnston K, Peacock S, Knowling M. Mabasa VH, et al. Among authors: peacock s. J Oncol Pharm Pract. 2008 Sep;14(3):105-12. doi: 10.1177/1078155208088695. Epub 2008 Jun 4. J Oncol Pharm Pract. 2008. PMID: 18524863

4

Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada.

Johnston KM, Marra CA, Connors JM, Najafzadeh M, Sehn L, Peacock SJ. Johnston KM, et al. Value Health. 2010 Sep-Oct;13(6):703-11. doi: 10.1111/j.1524-4733.2010.00737.x. Epub 2010 Jun 7. Value Health. 2010. PMID: 20561333 Free article.

5

Priority setting in healthcare: towards guidelines for the program budgeting and marginal analysis framework.

Peacock SJ, Mitton C, Ruta D, Donaldson C, Bate A, Hedden L. Peacock SJ, et al. Expert Rev Pharmacoecon Outcomes Res. 2010 Oct;10(5):539-52. doi: 10.1586/erp.10.66. Expert Rev Pharmacoecon Outcomes Res. 2010. PMID: 20950070 Review.

6

Erlotinib or docetaxel for second-line treatment of non-small cell lung cancer: a real-world cost-effectiveness analysis.

Cromwell I, van der Hoek K, Melosky B, Peacock S. Cromwell I, et al. Among authors: peacock s. J Thorac Oncol. 2011 Dec;6(12):2097-103. doi: 10.1097/JTO.0b013e31822f657a. J Thorac Oncol. 2011. PMID: 22052223 Free article.

7

Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.

Cromwell I, van der Hoek K, Malfair Taylor SC, Melosky B, Peacock S. Cromwell I, et al. Among authors: peacock s. Lung Cancer. 2012 Jun;76(3):472-7. doi: 10.1016/j.lungcan.2011.12.003. Epub 2012 Jan 9. Lung Cancer. 2012. PMID: 22226627

8

Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer.

Hedden L, O'Reilly S, Lohrisch C, Chia S, Speers C, Kovacic L, Taylor S, Peacock S. Hedden L, et al. Among authors: peacock s. Oncologist. 2012;17(2):164-71. doi: 10.1634/theoncologist.2011-0379. Epub 2012 Feb 2. Oncologist. 2012. PMID: 22302231 Free PMC article.

9

Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada.

Hedden L, Kennecke H, Villa D, Johnston K, Speers C, Kovacic L, Renouf DJ, Peacock S. Hedden L, et al. Among authors: peacock s. Eur J Cancer. 2012 Sep;48(13):1969-76. doi: 10.1016/j.ejca.2012.01.012. Epub 2012 Feb 9. Eur J Cancer. 2012. PMID: 22325838

10

Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers.

Pataky R, Armstrong L, Chia S, Coldman AJ, Kim-Sing C, McGillivray B, Scott J, Wilson CM, Peacock S. Pataky R, et al. Among authors: peacock s. BMC Cancer. 2013 Jul 10;13:339. doi: 10.1186/1471-2407-13-339. BMC Cancer. 2013. PMID: 23837641 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,087 results

Search Page